Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.

Grabar Law Office is investigating claims on behalf of Inspire Medical Systems, Inc. (NYSE: INSP) shareholders. The investigation concerns whether certain officers of Inspire Medical have breached their fiduciary duties owed to the company.

Current Inspire Medical shareholders who have continuously held Inspire Medical shares since prior to August 6, 2024, can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to them whatsoever.

BASIS OF THE INVESTIGATION: A recently filed securities fraud class action complaint alleges that Inspire Medical Systems, Inc. (NYSE: INSP), via certain of its officers, misled investors and/or failed to disclose that the company was having serious problems with the launch of its most important new product, a sleep apnea device called “Inspire V.” It is alleged that Inspire and certain of its officers falsely assured investors that Inspire had satisfied all regulatory, technical, and commercial conditions for the launch of its “next generation” product; that demand for Inspire V was high; and that the Company’s commercial launch of its new device was proceeding successfully.  In reality, none of these statements were true. Instead, and unbeknownst to investors, the Inspire V launch was a disaster. Contrary to Defendants’ public statements, demand for Inspire V was minimal because Inspire’s customers were already flush with inventory— older, unsold versions of Inspire’s sleep apnea device. Moreover, Defendants had failed to take basic steps to ensure clinician and payor uptake of the new device leading to massive delays in adoption.

On August 4, 2025, Inspire and its officers were forced to admit the truth, which once revealed, caused the price of Inspire stock to plummet by 32% and wiping out more than $1.5 billion in shareholder value.

WHAT YOU CAN DO NOW: If you have continuously held Inspire Medical shares since prior to August 6, 2024, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.  Contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.